MCID: END085
MIFTS: 47

Endometrial Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endometrial Serous Adenocarcinoma

MalaCards integrated aliases for Endometrial Serous Adenocarcinoma:

Name: Endometrial Serous Adenocarcinoma 11 5 14 16 71 33
Uterine Serous Carcinoma 11 75
Uterine Corpus Serous Adenocarcinoma 11
Uterine Papillary Serous Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:5750
NCIt 49 C27838
ICD11 33 225222541
UMLS 71 C0854924 C1336921

Summaries for Endometrial Serous Adenocarcinoma

Disease Ontology: 11 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary: Endometrial Serous Adenocarcinoma, also known as uterine serous carcinoma, is related to papillary serous adenocarcinoma and apocrine adenocarcinoma. An important gene associated with Endometrial Serous Adenocarcinoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Disease and PIP3 activates AKT signaling. The drugs Lenograstim and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in HCT116 cells

Wikipedia: 75 Uterine serous carcinoma is a malignant form of serous tumor that originates in the uterus. It is an... more...

Related Diseases for Endometrial Serous Adenocarcinoma

Diseases related to Endometrial Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 papillary serous adenocarcinoma 31.7 WT1 TP53 ERBB2 BRCA1
2 apocrine adenocarcinoma 30.5 TP53 PIK3CA ERBB2
3 ovarian serous carcinoma 30.5 WT1 TP53 MIR10B BRCA1
4 endometrial hyperplasia 30.3 TP53 PTEN ARID1A
5 papillary adenocarcinoma 30.3 TP53 MIR10B ERBB2 BRCA1
6 cervix carcinoma 30.2 TP53 PTEN PIK3CA MIR34C MIR139 ERBB2
7 endometrial adenocarcinoma 30.1 TP53 PTEN POLE MIR34C
8 gastrointestinal stromal tumor 30.0 TP53 PTEN PIK3CA ERBB2
9 wilms tumor 1 30.0 WT1 TP53 PTEN ERBB2 BRCA1
10 cervical squamous cell carcinoma 29.9 TP53 PTEN PIK3CA FBXW7 ARID1A
11 high grade glioma 29.9 TP53 PTEN PIK3CA MIR10B ATM
12 peripheral nervous system disease 29.9 TP53 PTEN MIR34B ERBB2 BRCA1 ATM
13 inherited cancer-predisposing syndrome 29.8 TP53 PTEN POLE BRCA1 ATM
14 bap1 tumor predisposition syndrome 29.8 TP53 PTEN POLE BRCA1 ATM
15 adenocarcinoma 29.8 TP53 PTEN PIK3CA ERBB2 CCNE1 ATM
16 carcinosarcoma 29.7 WT1 TP53 PTEN PPP2R1A PIK3CA FBXW7
17 hereditary breast ovarian cancer syndrome 29.7 TP53 PTEN POLE PIK3CA ERBB2 BRCA1
18 fanconi anemia, complementation group a 29.7 TP53 PTEN BRCA1 ATM ARID1A
19 ovary adenocarcinoma 29.6 WT1 TP53 PTEN PIK3CA ERBB2 BRCA1
20 mismatch repair cancer syndrome 29.4 TP53 PTEN POLE PIK3CA BRCA1 ATM
21 ovarian cancer 29.3 WT1 TP53 PTEN PPP2R1A PIK3CA MIR34C
22 endometrioid ovary carcinoma 29.3 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
23 mixed cell type cancer 29.3 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
24 endometrial cancer 29.1 WT1 TP53 PTEN PIK3CA FBXW7 ERBB2
25 uterine carcinosarcoma 29.1 TP53 PTEN PPP2R1A POLE PIK3CA FBXW7
26 lynch syndrome 29.1 TP53 PTEN PPP2R1A POLE PIK3CA MIR139
27 serous cystadenocarcinoma 28.6 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
28 breast cancer 28.0 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
29 epithelial-myoepithelial carcinoma 10.5
30 uterine anomalies 10.5
31 papillary carcinoma 10.4
32 maxillary sinus adenocarcinoma 10.3 TP53 ATM
33 apocrine adenosis of breast 10.3 TP53 ERBB2
34 esophagus small cell carcinoma 10.3 PIK3CA ERBB2
35 high-grade astrocytoma 10.3 TP53 PTEN
36 esophagus verrucous carcinoma 10.3 TP53 PIK3CA
37 parotid gland cancer 10.3 TP53 ERBB2
38 gestational ovarian choriocarcinoma 10.3 TP53 ERBB2
39 breast metaplastic carcinoma 10.3 TP53 ERBB2
40 basaloid lung carcinoma 10.3 TP53 BRCA1
41 comedo carcinoma 10.3 TP53 ERBB2
42 adrenocortical carcinoma, hereditary 10.3
43 primary agammaglobulinemia 10.3
44 pleomorphic adenoma carcinoma 10.3 TP53 ERBB2
45 familial ovarian cancer 10.3 TP53 POLE ATM
46 clear cell adenofibroma 10.3 PIK3CA ARID1A
47 penile benign neoplasm 10.3 TP53 PIK3CA
48 factor vii deficiency 10.2
49 neutropenia 10.2
50 ovarian epithelial cancer 10.2

Graphical network of the top 20 diseases related to Endometrial Serous Adenocarcinoma:



Diseases related to Endometrial Serous Adenocarcinoma

Symptoms & Phenotypes for Endometrial Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 9.91 POLE
2 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 POLE
3 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.91 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.91 BRCA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.91 PTEN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.91 PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 ERBB2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 ARID1A BRCA1 ERBB2 POLE PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.91 ARID1A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.91 ARID1A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.91 POLE
13 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.91 BRCA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.91 ERBB2 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.91 BRCA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.91 ARID1A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.91 ERBB2 POLE
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.91 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 ARID1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.91 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.91 ERBB2 POLE PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.91 PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.91 ARID1A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 ERBB2 POLE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.91 ERBB2 POLE PTEN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.91 POLE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.91 PTEN
29 Increased cell death in HCT116 cells GR00103-A-0 9.26 CHD4 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Endometrial Serous Adenocarcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.32 ARID1A ATM BRCA1 CCNE1 ERBB2 FBXW7
2 endocrine/exocrine gland MP:0005379 10.2 ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
3 normal MP:0002873 10.19 ARID1A BRCA1 CCNE1 ERBB2 FBXW7 MIR499A
4 embryo MP:0005380 10.17 ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
5 cellular MP:0005384 10.15 ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
6 muscle MP:0005369 10.08 ARID1A BRCA1 ERBB2 MIR499A PIK3CA PTEN
7 cardiovascular system MP:0005385 10.06 ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
8 immune system MP:0005387 10.03 ARID1A ATM BRCA1 CCNE1 CHD4 FBXW7
9 digestive/alimentary MP:0005381 10.01 BRCA1 CCNE1 ERBB2 FBXW7 MIR139 PIK3CA
10 reproductive system MP:0005389 9.85 ARID1A ATM BRCA1 CCNE1 ERBB2 FBXW7
11 mortality/aging MP:0010768 9.83 ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
12 integument MP:0010771 9.28 ATM BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA

Drugs & Therapeutics for Endometrial Serous Adenocarcinoma

Drugs for Endometrial Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
4
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
5
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
6
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
8
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
9
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
10 Estrogens Phase 2, Phase 3
11 Estrogen Receptor Antagonists Phase 2, Phase 3
12 Estrogen Antagonists Phase 2, Phase 3
13 Hormones Phase 2, Phase 3
14 Hormone Antagonists Phase 2, Phase 3
15 Aromatase Inhibitors Phase 2, Phase 3
16 Immunologic Factors Phase 2, Phase 3
17 Liposomal doxorubicin Phase 3
18 Adjuvants, Immunologic Phase 3
19 Immunosuppressive Agents Phase 2, Phase 3
20 Antineoplastic Agents, Immunological Phase 2, Phase 3
21 Hypoglycemic Agents Phase 2, Phase 3
22
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
23
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
24
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
25
Olaparib Approved Phase 2 763113-22-0 23725625
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
28
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
29
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
32
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
33
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
34
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
35
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
36
Trebananib Investigational Phase 2 894356-79-7
37
Onapristone Investigational Phase 2 96346-61-1 5311505
38
Cediranib Investigational Phase 2 288383-20-0 9933475
39
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
40
MK-1775 Investigational Phase 2 955365-80-7 24856436
41 Liver Extracts Phase 2
42 Immunoglobulin Fc Fragments Phase 2
43 Antineoplastic Agents, Hormonal Phase 2
44 Anti-Bacterial Agents Phase 2
45 Antibiotics, Antitubercular Phase 2
46 Anti-Infective Agents Phase 2
47 Epothilones Phase 2
48 Epothilone B Phase 2 4456137
49 Antifungal Agents Phase 2
50 Antiprotozoal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
2 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
4 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
5 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
6 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
7 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
8 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
9 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
10 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
11 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Completed NCT02728258 Phase 2 Copanlisib
12 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
13 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
14 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
15 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
17 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
18 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
19 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
20 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
21 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
22 A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer Recruiting NCT04719273 Phase 2 Extended-release Onapristone;Anastrozole
23 A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer Recruiting NCT03660826 Phase 2 Capivasertib;Cediranib;Cediranib Maleate;Olaparib
24 Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma Recruiting NCT04080284 Phase 2 Niraparib
25 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
26 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Recruiting NCT04030000 Phase 1, Phase 2 Paclitaxel/Carboplatin
27 A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT04814108 Phase 2 ZN-c3
28 A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
29 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
30 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
31 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
32 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Active, not recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
33 A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma Active, not recruiting NCT04590248 Phase 2 Adavosertib
34 Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer Not yet recruiting NCT05231122 Phase 2
35 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Terminated NCT02112552 Phase 2 Paclitaxel;Carboplatin
36 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Terminated NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
37 Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Withdrawn NCT03836157 Phase 2 Mirvetuximab Soravtansine;Bevacizumab
38 A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973 Completed NCT01935973 Phase 1 Trametinib;Uprosertib
39 Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
40 A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
41 Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
42 Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
43 A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies Recruiting NCT04585958 Phase 1 Olaparib
44 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
45 Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Ruxolitinib;Ruxolitinib Phosphate;Technetium Tc-99m Sodium Pertechnetate
46 A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma Active, not recruiting NCT03325634 Phase 1
47 A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
48 Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT03552471 Phase 1 Rucaparib Camsylate
49 First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours Not yet recruiting NCT05498597 Phase 1 AMT-151
50 Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers Completed NCT02315469

Search NIH Clinical Center for Endometrial Serous Adenocarcinoma

Genetic Tests for Endometrial Serous Adenocarcinoma

Anatomical Context for Endometrial Serous Adenocarcinoma

Organs/tissues related to Endometrial Serous Adenocarcinoma:

MalaCards : Uterus, Lymph Node, Breast, Endothelial, Liver, Cervix, Myeloid

Publications for Endometrial Serous Adenocarcinoma

Articles related to Endometrial Serous Adenocarcinoma:

(show top 50) (show all 562)
# Title Authors PMID Year
1
Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. 62
36428992 2022
2
Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. 62
36409196 2022
3
Targeted Therapies in the Treatment of Uterine Serous Carcinoma. 62
36447064 2022
4
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. 62
36243601 2022
5
Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma. 62
36096033 2022
6
HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. 62
36114027 2022
7
Endoscopic Surgery Using Ultrasonic Energy Device for Tracheal Metastatic Tumor. 62
34973186 2022
8
PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer. 62
36177381 2022
9
Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells. 62
35353883 2022
10
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. 62
35641325 2022
11
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. 62
35588308 2022
12
Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. 62
36010253 2022
13
[TXNDC17 protein overexpression in uterine papillary serous carcinoma is associated with clinicopathological characteristics and prognosis]. 62
36008321 2022
14
HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. 62
34320531 2022
15
Oncologic safety of laparoscopic surgery for women with apparent early-stage uterine serous carcinoma: A multi-institutional retrospective cohort study. 62
34561857 2022
16
Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. 62
35624045 2022
17
Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. 62
35949786 2022
18
Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. 62
35740505 2022
19
Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis. 62
35489712 2022
20
Endometrial Polyp in Postmenopausal Women. 62
35512230 2022
21
Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. 62
35216809 2022
22
Synchronous uterine serous carcinoma and ovarian sex cord stromal tumor (thecoma)-A rare first case report. 62
35435389 2022
23
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. 62
35434236 2022
24
Evaluation of Saccharomyces cerevisiae-like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma. 62
35283446 2022
25
Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma. 62
35024404 2022
26
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. 62
34952707 2022
27
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. 62
34921012 2022
28
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. 62
34716177 2022
29
The top 100 most cited papers on endometrial carcinoma: A bibliometric analysis. 62
36059668 2022
30
Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer. 62
35106124 2022
31
Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer. 62
35812065 2022
32
Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in uterine papillary serous carcinoma. 62
34980663 2022
33
Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. 62
34753617 2022
34
Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. 62
34508766 2021
35
Linking altered microRNA expression to racial disparities in uterine serous carcinoma. 62
34836615 2021
36
Inspection for micrometastasis is essential for predicting the prognosis of serous endometrial intraepithelial carcinoma: Case report and literature review. 62
34494349 2021
37
MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. 62
34607711 2021
38
Concomitant diagnosis of endometrial and breast cancer - does the sequence matters? 62
34621946 2021
39
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. 62
34452746 2021
40
Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. 62
34761096 2021
41
Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel. 62
34786186 2021
42
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. 62
34898589 2021
43
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. 62
34372971 2021
44
A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. 62
34018286 2021
45
Matched-pair Analysis for Survival Endpoints Between Women With Early-stage Uterine Carcinosarcoma and Uterine Serous Carcinoma. 62
34265785 2021
46
Uterine serous carcinoma: key advances and novel treatment approaches. 62
34210768 2021
47
Impact of positive cytology in uterine serous carcinoma: A reassessment. 62
34345643 2021
48
Uterine serous carcinoma. 62
33934848 2021
49
Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases. 62
33870589 2021
50
Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma. 62
35047191 2021

Variations for Endometrial Serous Adenocarcinoma

ClinVar genetic disease variations for Endometrial Serous Adenocarcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ATM DEL Pathogenic
1174013 GRCh37: 11:108098332-108236255
GRCh38:

Copy number variations for Endometrial Serous Adenocarcinoma from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA1 Uterine serous papillary cancer

Expression for Endometrial Serous Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Serous Adenocarcinoma.

Pathways for Endometrial Serous Adenocarcinoma

Pathways related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 TP53 PTEN PPP2R1A PIK3CA FBXW7 ERBB2
2
Show member pathways
13.01 CHD4 ERBB2 PIK3CA PPP2R1A PTEN TP53
3
Show member pathways
12.9 BRCA1 CCNE1 PIK3CA PPP2R1A PTEN TP53
4
Show member pathways
12.87 TP53 PTEN PPP2R1A CHD4 CCNE1 BRCA1
5
Show member pathways
12.7 TP53 PPP2R1A CCNE1 BRCA1 ATM
6 12.64 TP53 PTEN PIK3CA CCNE1 BRCA1 ATM
7
Show member pathways
12.53 TP53 POLE FBXW7 CCNE1 BRCA1 ATM
8 12.45 ATM BRCA1 CCNE1 PPP2R1A TP53
9
Show member pathways
12.41 TP53 PTEN PIK3CA ERBB2
10
Show member pathways
12.38 TP53 PIK3CA ERBB2 ATM
11
Show member pathways
12.37 TP53 PTEN PIK3CA ERBB2 BRCA1 ATM
12
Show member pathways
12.31 PPP2R1A FBXW7 CCNE1 BRCA1
13
Show member pathways
12.19 TP53 POLE CCNE1 ATM
14
Show member pathways
12.17 TP53 PTEN PIK3CA ERBB2
15
Show member pathways
12.12 TP53 PTEN CCNE1 BRCA1 ATM
16 12.09 TP53 PTEN BRCA1 ATM
17
Show member pathways
12.06 TP53 CCNE1 BRCA1 ATM
18
Show member pathways
12.05 TP53 PPP2R1A CCNE1 ATM
19 11.86 TP53 PTEN PIK3CA CCNE1
20
Show member pathways
11.85 TP53 BRCA1 ATM
21 11.84 PTEN MIR34C MIR34B CCNE1
22 11.79 TP53 POLE CCNE1
23
Show member pathways
11.78 TP53 CCNE1 BRCA1 ATM
24 11.77 TP53 PTEN PIK3CA ERBB2 ATM
25
Show member pathways
11.76 TP53 BRCA1 ATM
26 11.75 ATM BRCA1 TP53
27
Show member pathways
11.71 TP53 PPP2R1A ATM
28 11.7 TP53 PTEN PPP2R1A
29 11.7 ERBB2 PIK3CA PTEN TP53
30 11.64 CCNE1 BRCA1 ATM
31
Show member pathways
11.57 TP53 PTEN PIK3CA
32 11.42 ATM BRCA1 CCNE1 TP53
33 11.31 TP53 PTEN BRCA1 ATM
34 11.27 TP53 PTEN ATM
35 11.26 TP53 MIR449B MIR34C MIR34B CCNE1 ATM
36 11.13 ATM BRCA1 CCNE1 TP53
37 11.02 TP53 CCNE1 BRCA1 ATM
38 11.02 TP53 PTEN PIK3CA FBXW7 ERBB2 BRCA1
39 10.74 TP53 CCNE1 BRCA1 ATM
40 10.71 BRCA1 ATM
41 10.36 TP53 CCNE1 ATM

GO Terms for Endometrial Serous Adenocarcinoma

Biological processes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 9.86 TP53 PTEN CCNE1 BRCA1 ATM
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.85 PTEN PIK3CA ERBB2
3 female meiotic nuclear division GO:0007143 9.78 PPP2R1A ATM
4 negative regulation of protein kinase B signaling GO:0051898 9.76 PTEN MIR34C MIR34B
5 negative regulation of cell growth GO:0030308 9.76 BRCA1 PPP2R1A TP53 WT1
6 heart development GO:0007507 9.61 WT1 TP53 PTEN ERBB2 ATM
7 positive regulation of connective tissue replacement GO:1905205 9.43 MIR34C MIR34B
8 chromosome organization involved in meiotic cell cycle GO:0070192 9.4 CCNE1 ATM
9 miRNA-mediated gene silencing GO:0035195 9.4 MIR499A MIR449B MIR34C MIR34B MIR139 MIR135A1
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.32 MIR34C MIR34B

Molecular functions related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR499A MIR34C MIR34B MIR139 MIR10B
2 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR499A MIR34C MIR34B MIR139 MIR135A1 MIR10B

Sources for Endometrial Serous Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....